Study on PAD and CAS Based on Omics and Imaging

Launched by YIJIE NING · Mar 31, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring two conditions called Peripheral Artery Disease (PAD) and Carotid Artery Stenosis (CAS). The goal is to better understand how these diseases develop and progress by using advanced imaging techniques and analyzing patient samples. Researchers will look at the blood vessels using special imaging methods and collect information about the cells and molecules in the body. By combining these findings with computer technology, they hope to create better tools for diagnosing these conditions and finding more personalized treatments.

To participate in this study, you need to be a patient between the ages of 18 and 85 who has been diagnosed with either PAD or CAS. It's important that you are conscious and fully understand the study before giving your consent to join. However, there are some health conditions that would exclude you from participating, such as severe heart problems, significant liver or kidney issues, or if you've had certain treatments for PAD before. If you qualify, you can expect to undergo various imaging tests and provide samples for analysis, which will help researchers uncover new information about these diseases.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The study subjects are inpatients from the Department of Vascular Surgery at the Second Hospital of Shanxi Medical University.
• • 2. Males or females aged between 18 and 85 years.
• • 3. Diagnosed with Peripheral Artery Disease (PAD) or Carotid Artery Stenosis (CAS).
• • 4. Participants are conscious, fully informed about the study content, and have signed the informed consent form, agreeing to participate in this study.
• Exclusion Criteria:
• • 1. Non-atherosclerotic stenosis (e.g., vasculitis or dissection).
• • 2. PAD patients who have previously undergone interventional treatments (e.g., balloon angioplasty or stent placement) and/or surgical procedures.
• • 3. Patients with heart failure classified as NYHA Class II-IV or those with a history of coronary artery disease.
• • 4. Patients with acute infections, tumors, severe arrhythmias, psychiatric disorders, or drug/alcohol addiction.
• • 5. Significant liver dysfunction or a history of liver diseases, including: Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding twice the upper limit of normal. History of cirrhosis, hepatic encephalopathy, esophageal varices, or portosystemic shunt.
• • 6. Significant renal dysfunction or a history of kidney diseases, including: Serum creatinine levels exceeding 1.5 times the upper limit of normal. History of dialysis or nephrotic syndrome.
• • 7. Pregnant women, those planning to become pregnant, or breastfeeding women.
• • 8. Participation in other clinical trials within the past 3 months.
• • 9. Refusal to sign the informed consent form or participate in this study.